Market Tracker

11/17 5:15pm ET

Nektar Therapeutics (NASDAQ:NKTR)

44.99
Delayed Data
As of Nov 17
 0.00 / 0.00%
Today’s Change
11.41
Today|||52-Week Range
46.98
+266.67%
Year-to-Date
Company News For Nov 14, 2017
Nov 14 / Zacks.com - Paid Partner Content
Nektar (NKTR) Q3 Earnings & Sales Surpass, Sales View Up
Nov 08 / Zacks.com - Paid Partner Content
Rev's Forum: Problems Simmer, but It's Still Too Early for a Bearish Bias
Nov 14 / TheStreet.com - Paid Partner Content
Nektar Therapeutics (NKTR) Jumps: Stock Rises 10.54%
Nov 08 / Zacks.com - Paid Partner Content
Nektar/Bristol-Myers' Combo Trial Positive in Phase I/II
Nov 13 / Zacks.com - Paid Partner Content
Implied Volatility Surging for Nektar (NKTR) Stock Options
Nov 07 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close44.99
Today’s open44.75
Day’s range44.20 - 46.98
Volume3,677,856
Average volume (3 months)1,638,534
Market cap$7.1B
Dividend yield--
Data as of 4:00pm ET, 11/17/2017

Growth & Valuation

Earnings growth (last year)-80.33%
Earnings growth (this year)+31.41%
Earnings growth (next 5 years)-7.38%
Revenue growth (last year)-28.32%
P/E ratioNM
Price/Sales10.35
Price/Book78.22

Competitors

 Today’s
change
Today’s
% change
AVXSAveXis Inc0.000.00%
ONCESpark Therapeutics I...0.000.00%
XONIntrexon Corp0.000.00%
JUNOJuno Therapeutics In...0.000.00%
Data as of 4:02pm ET, 11/17/2017

Financials

Next reporting dateFebruary 28, 2018
EPS forecast (this quarter)-$0.34
Annual revenue (last year)$165.4M
Annual profit (last year)-$153.5M
Net profit margin-92.80%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Howard W. Robin
Chief Operating Officer &
Senior Vice President
John Nicholson
Corporate headquarters
San Francisco, California

Forecasts